IO Biotech to Present at the 45th Annual Cowen Health Care Conference
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory, off-the-shelf therapeutic cancer vaccines, has announced its participation in the 45th Annual Cowen Health Care Conference. The company's presentation will feature updates on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted).
The presentation will be delivered by Mai-Britt Zocca, PhD, President and CEO, on Wednesday, March 5, 2025, from 2:30-3:00 PM EST in Boston, MA. The company's leadership team, including CFO Amy Sullivan and CMO Qasim Ahmad, MD, will be available for one-on-one investor meetings during the conference. A webcast replay will be accessible on the company's website for 90 days following the presentation.
IO Biotech (Nasdaq: IOBT), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di vaccini terapeutici contro il cancro, modulanti l'immunità e pronti all'uso, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute Cowen. La presentazione dell'azienda includerà aggiornamenti sullo sviluppo e sui preparativi per il lancio di Cylembio™ (imsapepimut ed etimupepimut, adiuvati).
La presentazione sarà tenuta da Mai-Britt Zocca, PhD, Presidente e CEO, mercoledì 5 marzo 2025, dalle 14:30 alle 15:00 EST a Boston, MA. Il team dirigenziale dell'azienda, inclusi il CFO Amy Sullivan e il CMO Qasim Ahmad, MD, sarà disponibile per incontri individuali con gli investitori durante la conferenza. Una riproduzione del webcast sarà accessibile sul sito web dell'azienda per 90 giorni dopo la presentazione.
IO Biotech (Nasdaq: IOBT), una empresa biofarmacéutica en etapa clínica centrada en desarrollar vacunas terapéuticas contra el cáncer que modulan la inmunidad y están listas para usar, ha anunciado su participación en la 45ª Conferencia Anual de Salud Cowen. La presentación de la empresa incluirá actualizaciones sobre el desarrollo y los preparativos para el lanzamiento de Cylembio™ (imsapepimut y etimupepimut, adyuvados).
La presentación será realizada por Mai-Britt Zocca, PhD, Presidenta y CEO, el miércoles 5 de marzo de 2025, de 2:30 a 3:00 PM EST en Boston, MA. El equipo directivo de la empresa, que incluye a la CFO Amy Sullivan y al CMO Qasim Ahmad, MD, estará disponible para reuniones individuales con inversores durante la conferencia. Una repetición de la transmisión web estará disponible en el sitio web de la empresa durante 90 días después de la presentación.
IO Biotech (Nasdaq: IOBT)는 면역 조절 기능을 갖춘 즉시 사용할 수 있는 치료용 암 백신 개발에 중점을 둔 임상 단계의 생명공학 회사로, 제45회 카우엔 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 발표에서는 Cylembio™ (imsapepimut 및 etimupepimut, 보조제 포함)의 개발 및 출시 준비에 대한 업데이트가 포함될 것입니다.
발표는 Mai-Britt Zocca, PhD가 진행하며, 2025년 3월 5일 수요일, 오후 2시 30분부터 3시까지 EST, 매사추세츠주 보스턴에서 진행됩니다. CFO Amy Sullivan과 CMO Qasim Ahmad, MD를 포함한 회사의 경영진은 컨퍼런스 동안 투자자와의 일대일 미팅을 위해 대기합니다. 발표 후 90일 동안 회사 웹사이트에서 웹캐스트 재생을 확인할 수 있습니다.
IO Biotech (Nasdaq: IOBT), une entreprise bio-pharmaceutique en phase clinique axée sur le développement de vaccins thérapeutiques contre le cancer modulant l'immunité et prêts à l'emploi, a annoncé sa participation à la 45e Conférence Annuelle de la Santé Cowen. La présentation de l'entreprise comprendra des mises à jour sur le développement et les préparatifs de lancement de Cylembio™ (imsapepimut et etimupepimut, adjuvants).
La présentation sera assurée par Mai-Britt Zocca, PhD, Présidente et CEO, le mercredi 5 mars 2025, de 14h30 à 15h00 EST à Boston, MA. L'équipe dirigeante de l'entreprise, y compris la CFO Amy Sullivan et le CMO Qasim Ahmad, MD, sera disponible pour des réunions individuelles avec les investisseurs pendant la conférence. Un replay du webinaire sera accessible sur le site web de l'entreprise pendant 90 jours après la présentation.
IO Biotech (Nasdaq: IOBT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von immunmodulatorischen, sofort einsatzbereiten therapeutischen Krebsimpfstoffen konzentriert, hat seine Teilnahme an der 45. jährlichen Cowen Gesundheitskonferenz bekannt gegeben. Die Präsentation des Unternehmens wird Updates zur Entwicklung und zu den Vorbereitungen für den Launch von Cylembio™ (imsapepimut und etimupepimut, adjuvant) enthalten.
Die Präsentation wird von Mai-Britt Zocca, PhD, Präsidentin und CEO, am Mittwoch, den 5. März 2025, von 14:30 bis 15:00 Uhr EST in Boston, MA, gehalten. Das Führungsteam des Unternehmens, einschließlich CFO Amy Sullivan und CMO Qasim Ahmad, MD, wird während der Konferenz für persönliche Investorengespräche zur Verfügung stehen. Eine Wiederholung des Webcasts wird für 90 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
- Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that Mai-Britt Zocca, PhD, President and CEO, will present a company overview at the 45th Annual Cowen Health Care Conference to be held March 3-5, 2025 in Boston, MA. Dr. Zocca, joined by Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO, will also be hosting one-on-one investor meetings during the conference.
Presentation Details
Date and Time: Wednesday, March 5, 2025, 2:30-3:00 PM EST
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://wsw.com/webcast/cowen177/iobt/2022522
A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.
About Cylembio™
Cylembio™ (imsapepimut and etimupepimut, adjuvanted), is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the three ongoing company-sponsored clinical trials is now complete.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio™ (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Cylembio is a trademark of IO Biotech ApS.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
When is IO Biotech presenting at the 2025 Cowen Health Care Conference?
What product update will IO Biotech (IOBT) discuss at the Cowen conference?
How long will the IO Biotech (IOBT) Cowen conference presentation webcast be available?
Which IO Biotech executives will be available for meetings at the Cowen conference?
